Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CLDX
CLDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLDX News
Major Wall Street Rating Updates on Monday
15h ago
CNBC
Celldex Closes $345 Million Public Offering of 11.9 Million Shares
Apr 06 2026
Newsfilter
Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
Apr 02 2026
seekingalpha
Celldex Therapeutics Prices Public Offering at $29 per Share
Apr 02 2026
NASDAQ.COM
Celldex Announces Public Offering of Shares
Apr 02 2026
Newsfilter
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
Apr 02 2026
Yahoo Finance
Celldex Initiates Underwritten Public Offering to Support New Drug Launch
Apr 01 2026
seekingalpha
Celldex's Barzolvolimab Enhances Quality of Life in Chronic Urticaria Patients
Mar 27 2026
Newsfilter
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
Mar 21 2026
Yahoo Finance
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
Mar 02 2026
NASDAQ.COM
Celldex Presents Positive Data on Barzolvolimab for ColdU and SD Treatment
Mar 01 2026
Newsfilter
Celldex Reports Positive Data on Barzolvolimab Efficacy
Feb 27 2026
Newsfilter
Celldex Completes Enrollment for Barzolvolimab Trial Ahead of Schedule
Feb 26 2026
stocktwits
Celldex Q4 Earnings Miss Expectations
Feb 25 2026
seekingalpha
Celldex Completes Enrollment in Chronic Spontaneous Urticaria Studies Ahead of Schedule
Feb 25 2026
Yahoo Finance
Update: Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab; Shares Rise
Feb 25 2026
Yahoo Finance
Show More News
